Skip to main content

Table 1 Donor, Recipient and Transplant baseline characteristics by donor age < 50 years between 50 and 69 years and ≥ 70 years

From: Relationship between early proteinuria and long term outcome of kidney transplanted patients from different decades of donor age

 

All patients

(1127 pts)

Donors < 50 yrs.

(339 pts)

Donors 50–69 yrs.

(496 pts)

Donors ≥70 yrs.

(292 pts)

P value

1A - Donor characteristics

 M/F (%)

578/549 (51/49)

215/124 (63/37)

229/267 (46/54)

134/158 (46/54)

< 0,01

 eGFR CG (ml/min)

99,38

126,89 ± 40,65

94,68 ± 34,83

76,78 ± 28,22

< 0,01

 eGFR CKD-EPI(ml/min)

83,65

103,51 ± 30,39

85,79 ± 25,38

79,7 ± 22,03

< 0,01

 Hypertension (%)

511 (49)

66 (21)

259 (57)

186 (68)

< 0,01

 Diabetes mellitus (%)

78 (8)

9 (3)

49 (12)

20 (8)

< 0,01

 Cerebrovascular cause of death (%)

747 (72)

159 (52)

370 (80)

218 (81)

< 0,01

1B - Recipient characteristics

 M/F (%)

721/406 (64/36)

217/122 (64/36)

305/191 (61/39)

199/93 (68/32)

0,18

 Mean age (Yrs)

59.17 ± 9.43

43,99 ± 10,69

55,31 ± 9,66

62,73 ± 7,93

< 0,01

 1st Tx/ More than 1 Tx (%)

972/155 (87/13)

277/62

(82/18)

427/69 (86/14)

268/24

(92/8)

< 0,01

 SKT/DKT (%)

1082/45

(96/4)

339/0

(100/0)

481/15 (97/3)

262/30

(90/10)

< 0,01

 HD/PD (%)

873/ 308 (79/28)

279/73 (86/22)

390/136 (80/28)

204/99 (71/35)

< 0,01

 Pretransplant DM 1 or 2/type 2 (%)

95/79 (10,2/7)

19/14 (6/4)

48/35 (10/7)

16/30 (16/11)

< 0,01

 Pretransplat Hypertension (%)

939 (86)

267 (81)

420 (88)

252 (91)

< 0,01

 Pretransplant Cardiopathy (%)

358 (32)

90 (26)

164(33)

104 (36)

< 0,01

 Pretransplant HCV POS (%)

91 (8)

26 (8)

44 (9)

21 (8)

0,78

1C - Transplant characteristics

 HLA A/B/DR MM (0–2/3–4/5–6) %

48/46/6

32/62/6

34/57/9

42/54/4

0,27

 PRA zero (CDC) at transplantation %

66,3

63

63

75,4

0,13

 Cold ischemia time (hours)

16,16 ± 5,22

15,89 ± 5,37

17,80 ± 4,98

18,25 ± 4,64

0,03

 DGF (%)

298 (28)

74 (23)

135 (29)

89 (32)

0,04

Induction Therapy

< 0,01

 ATG (%)

21 (2)

3 (1)

3 (1)

9 (3)

 

 Basiliximab (%)

1080 (98)

319 (98)

479 (98)

282 (99)

Mantaining Therapy

< 0,01

 Tacrolimus (%)

848 (79)

286 (87)

360 (77)

202 (73)

 

 Cyclosporine (%)

181 (17)

32 (10)

95 (20)

54 (20)

 mTORi (%)

83 (8)

27 (11)

31 (7)

25 (9)

 mTORi at 1 yr(%)

169 (15)

77 (23)

59 (12)

33 (11)

< 0,01

 ACE/ARB (%)

368 (33)

190 (56)

117 (24)

61 (21)

< 0,01

End f-up Mantaining Therapy (%)

< 0,01

  Tacrolimus (%)

839 (78)

271 (83)

374 (79)

194 (69)

 

 Cyclosporine (%)

133 (12)

27 (8)

64 (13)

42 (15)

 mTORi (%)

255 (24)

56 (17)

124 (26)

73 (26)

  1. eGFR = estimated Glomerular filtration rate; CG = Cockroft-Gault formula; CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration; SKT = Single Kidney Transplantation; DKT = Dual Kidney Transplantation; PD = Peritoneal Dialysis; HD = Haemodialysis; DM = Diabetes Mellitus; HCV = Hepatitis C virus; HLA = Human Leucocyte Antigens; MM = Mismatch; PRA = Panel Reactive Antibodies; CDC = Cell Dependent Cytotoxicity; ATG = anti-thymocite globulin; mTORi = mammalian target of rapamycin inhibitors; ACE = angyotensin converting enzyme; ARB = Angiotensin Receptor Blockers; DGF = delayed graft function